Wildy Logo
(020) 7242 5778
enquiries@wildy.com

Book of the Month

Cover of Company Directors: Duties, Liabilities and Remedies

Company Directors: Duties, Liabilities and Remedies

Edited by: Mark Arnold KC, Simon Mortimore KC
Price: £275.00

Lord Denning: Life, Law and Legacy



  


Welcome to Wildys

Watch


NEW EDITION Pre-order Mortgage Receivership: Law and Practice



 Stephanie Tozer, Cecily Crampin, Tricia Hemans
Practical guidance to relevant law & procedure


Offers for Newly Called Barristers & Students

Special Discounts for Newly Called & Students

Read More ...


Secondhand & Out of Print

Browse Secondhand Online

Read More...


EU Competition Law and Pharmaceuticals

Edited by: Wolf Sauter, Marcel Canoy, Jotte Mulder

ISBN13: 9781802204407
Published: November 2022
Publisher: Edward Elgar Publishing Limited
Country of Publication: UK
Format: Hardback
Price: £114.00



Low stock.

This timely book discusses the application of the EU competition rules to pharmaceuticals, covering the prohibitions on anticompetitive agreements and abuse of dominance, and merger control.

The author team comprises academic experts and private practitioners who analyse recent case law at both EU (and UK) and Member State levels – in the context of current issues and future trends, including those related to COVID-19 – and examine the impact of competition law on the behaviour of the pharmaceutical industry. The book carefully considers the balance between competition and innovation, as well as between competition and regulation. It concludes that competition and regulation are not alternatives, but complementary, and that novel ways of taking into account risk and real innovation through competition assessments have been developed.

Integrating an overview of competition law, IP law and pharmaceutical regulation, this book will be an ideal read for scholars and graduate students, as well as private and public practitioners interested in pharmaceutical and European law.

Subjects:
Competition Law
Contents:
Foreword
PART I. INTRODUCTION, LEGAL AND ECONOMIC CONTEXT
1. Introduction
Marcel Canoy, Jotte Mulder and Wolf Sauter
2. Excessive pricing doctrine in the pharmaceutical sector: the space for reform
Frederick M. Abbott
3. Evergreening exclusive rights in pharmaceutical products: the case of SPCs, paediatric extensions and orphan drugs
Frantzeska Papadopoulou
4. The economics of patents and innovation in pharma
Marcel Canoy and Matthijs Versteegh
PART II. THE COMPETITION CASES
SECTION IIA PAY FOR DELAY AND PATENT STRATEGIES
5. Settlement agreements acknowledging patent validity in the United Kingdom
Okeoghene Odudu
6. Anticompetitive pharmaceutical patent settlements: the EU cases on pay-for-delay
Jotte Mulder and Wolf Sauter
SECTION IIB. EXCESSIVE PRICING
7. The Aspen case of the Italian Competition Authority
Claudia Desogus
8. Unfair pricing: policy considerations and recent experience in the pharmaceutical sector
Andrew Groves and Lourenço Ventura
9. Temporary dominance and excessive pharmaceutical pricing – CD Pharma (Denmark)
Behrang Kianzad
10. Excessive pricing for pharmaceuticals in the Netherlands: the Leadiant case
Freek Bruggert and Clara Ceulemans
11. The EU Aspen decision: the European Commission’s first excessive pricing decision in the pharmaceutical market
Harald Mische
SECTION IIC. DISPARAGEMENT AND MISLEADING INFORMATION
12. Disparagement: the European Union and France
Adrien Giraud, Juliette Raffaitin and Constance Dobelmann
13. The dissemination of misleading information in the pharmaceutical market: the Italian experience
Margherita Colangelo
SECTION IID. MERGERS AND PARALLEL TRADE
14. EU merger control in the pharmaceutical sector: an overview
Jan Truijens Martinez
15. Taking stock of the single market imperative in the Court’s case law on parallel trade in pharmaceuticals: are matters as settled as they seem?
Jotte Mulder
PART III. FUTURE DIRECTIONS
16. Towards responsive enforcement of EU antitrust in pharmaceuticals
Wolf Sauter
17. Excessive pricing in pharmaceuticals: perspectives from EU antitrust and regulation
Giorgio Monti and Leigh Hancher
18. Tackling grand challenges with competition law: lessons from the pandemic
Ioannis Lianos, Timo Minssen and Christy Kollmar